<DOC>
	<DOC>NCT00089674</DOC>
	<brief_summary>This study will evaluate AMG 162 in the treatment of bone loss in subjects undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer.</brief_summary>
	<brief_title>AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Other criteria also apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Bone Loss with Prostate Cancer</keyword>
	<keyword>Treatment of bone loss in patients undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer (PC).</keyword>
</DOC>